Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

mAbxience

Tracked across 1 events · 8 articles · First seen Sep 18, 2026 · Last active Sep 18, 2026

Sentiment
25
Attention
2
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
2 25
Business
mAbxience, a majority-owned company of Fresenius (company) with partial ownership from Insud Pharma, and Novartis — Sandoz announced a licensing, development, manufacturing and commercialization agreement for a proposed emicizumab biosimilar candidate referencing Hemlibra, indicated for…
Impact: mAbxience is the development and manufacturing lead for the emicizumab biosimilar, gaining pipeline expansion into hemophilia A and rare diseases and reinforcing its biosimilars platform.
Sep 18, 2026 · 8 articles
95 mAbxience signed collaboration agreement Novartis — SandozmAbxience Sandoz...
70 mAbxience granted exclusive commercialization rights Novartis — SandozmAbxience Sandoz...
60 mAbxience took development manufacturing responsibilitymAbxience Sandoz...
ERGEN INTELLIGENCE
Track mAbxience live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.